In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.37 a new company low.

Within Biotechnology & Pharmaceuticals industry 128 other companies have achieved higher Quick Ratio than Neurocrine Biosciences Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1347 to 2693.

Explain Quick Ratio?
How much Cash & cash equivalents NBIX�s has?
What are NBIX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NBIX Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	91.49 %	59.06 %	16.33 %	48.48 %	37.09 %
Y / Y Cash & cash equivalent Change	-59.97 %	39.5 %	37.57 %	-9.22 %	-6.09 %
Quick Ratio MRQ	0.37	1.58	1.82	1.75	1.79
NBIX's Total Ranking	# 2693	# 1347	# 657	# 1052	# 1060
Seq. Current Liabilities Change	25.78 %	2.5 %	27.18 %	16.79 %	4.48 %
Seq. Cash & cash equivalent Change	-70.33 %	-11.09 %	32.8 %	14.27 %	3.4 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 129
Healthcare Sector	# 757
Overall Market	# 2693

Quick Ratio Statistics
High	Average	Low
24.36	7.26	0.37
(Mar 31 2015)		(Jun 30 2026)

Financial Statements
Neurocrine Biosciences Inc 's Current Liabilities	$ 1,046 Millions	Visit NBIX's Balance sheet
Neurocrine Biosciences Inc 's Cash & cash equivalent	$ 391 Millions	Visit NBIX's Balance sheet
Source of NBIX's Sales		Visit NBIX's Sales by Geography

Cumulative Neurocrine Biosciences Inc 's Quick Ratio

NBIX's Quick Ratio for the trailling 12 Months

NBIX Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	51.48 %	38.02 %	12.51 %	3.79 %	-14.83 %
Y / Y Cash & cash equivalent TTM Growth	1.86 %	14.01 %	-0.86 %	-8.85 %	-3.5 %
Quick Ratio TTM	1.29	1.73	1.79	1.71	1.92
Total Ranking TTM	# 3959	# 3098	# 2087	# 2856	# 771
Seq. Current Liabilities TTM Growth	17.68 %	12.26 %	4.74 %	9.48 %	7.21 %
Seq. Cash & cash equivalent TTM Growth	-11.97 %	8.26 %	9.84 %	-2.68 %	-1.48 %

Quick ratio ranking by company, industry and sector >> Back to NBIX Financial Strength Comparisons >> Go to Compare NBIX Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q2 2026 to $1,046.10 millions, cumulative Quick Ratio decreased to 1.29 below the Neurocrine Biosciences Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 141 other companies have achieved higher Quick Ratio than Neurocrine Biosciences Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3098 to 3959.

Explain Quick Ratio?
How much Cash & cash equivalents NBIX�s has?
What are NBIX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 142
Healthcare Sector	# 890
Within the Market	# 3959

trailing twelve months Quick Ratio Statistics
High	Average	Low
19.43	7.49	1.39
(Sep 30 2015)		(Jun 30 2026)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Liminatus Pharma Inc	0.99	$ 3.017 Millions	$ 3.040 Millions
Elutia Inc	0.95	$ 19.896 Millions	$ 21.045 Millions
Jasper Therapeutics Inc	0.93	$ 7.314 Millions	$ 7.845 Millions
Protalix Biotherapeutics inc	0.90	$ 28.140 Millions	$ 31.391 Millions
Vivosim Labs Inc	0.88	$ 1.670 Millions	$ 1.893 Millions
Senti Biosciences Holdings Inc	0.83	$ 13.124 Millions	$ 15.765 Millions
Pelthos Therapeutics Inc	0.78	$ 24.776 Millions	$ 31.959 Millions
Ocugen Inc	0.75	$ 100.051 Millions	$ 133.080 Millions
Sab Biotherapeutics Inc	0.71	$ 8.267 Millions	$ 11.705 Millions
Vaxcyte Inc	0.68	$ 183.190 Millions	$ 271.277 Millions
Halozyme Therapeutics Inc	0.61	$ 231.081 Millions	$ 375.965 Millions
Silexion Therapeutics Corp	0.57	$ 2.258 Millions	$ 3.976 Millions
Atlantic Coastal Acquisition Corp Ii	0.52	$ 4.291 Millions	$ 8.225 Millions
Surrozen Inc	0.50	$ 102.039 Millions	$ 203.292 Millions
Pluri Inc	0.40	$ 13.126 Millions	$ 32.719 Millions
Outlook Therapeutics Inc	0.39	$ 11.242 Millions	$ 28.679 Millions
Neurocrine Biosciences Inc	0.37	$ 390.500 Millions	$ 1,046.100 Millions
Curis Inc	0.37	$ 5.100 Millions	$ 13.675 Millions
Creative Medical Technology Holdings Inc	0.36	$ 0.250 Millions	$ 0.699 Millions
Xtant Medical Holdings Inc	0.33	$ 9.870 Millions	$ 29.963 Millions
Champions Oncology Inc	0.23	$ 4.358 Millions	$ 18.729 Millions
ADAPTIN BIO, INC.	0.22	$ 0.670 Millions	$ 3.036 Millions
Armata Pharmaceuticals Inc	0.10	$ 23.952 Millions	$ 250.199 Millions
Agenus Inc	0.08	$ 18.738 Millions	$ 231.820 Millions

Date modified: 2026-08-31T07:05:19+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.